Huang Y - Search Results

1

Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards.

Zhang D, Zhang H, Aranibar N, Hanson R, Huang Y, Cheng PT, Wu S, Bonacorsi S, Zhu M, Swaminathan A, Humphreys WG. Zhang D, et al. Among authors: huang y. Drug Metab Dispos. 2006 Feb;34(2):267-80. doi: 10.1124/dmd.105.007153. Epub 2005 Nov 9. Drug Metab Dispos. 2006. PMID: 16280454 Clinical Trial.

2

Microbial transformation of 2-amino-4-methyl-3-nitropyridine.

Tully T, Liu M, Huang Y, Ye Q, Patel RN, Goswami A. Tully T, et al. Among authors: huang y. J Ind Microbiol Biotechnol. 2012 Dec;39(12):1789-99. doi: 10.1007/s10295-012-1189-7. Epub 2012 Aug 29. J Ind Microbiol Biotechnol. 2012. PMID: 22926342

3

Influence of formaldehyde impurity in polysorbate 80 and PEG-300 on the stability of a parenteral formulation of BMS-204352: identification and control of the degradation product.

Nassar MN, Nesarikar VN, Lozano R, Parker WL, Huang Y, Palaniswamy V, Xu W, Khaselev N. Nassar MN, et al. Among authors: huang y. Pharm Dev Technol. 2004;9(2):189-95. doi: 10.1081/pdt-120030249. Pharm Dev Technol. 2004. PMID: 15202578

4

Degradation pathways of a corticotropin-releasing factor antagonist in solution and solid states.

Badawy S, Hussain M, Zhao F, Ye Q, Huang Y, Palaniswamy V. Badawy S, et al. Among authors: huang y. J Pharm Sci. 2009 Aug;98(8):2636-47. doi: 10.1002/jps.21637. J Pharm Sci. 2009. PMID: 19072860

5

Degradation of a lyophilized formulation of BMS-204352: identification of degradants and role of elastomeric closures.

Nassar MN, Nesarikar VV, Lozano R, Huang Y, Palaniswamy V. Nassar MN, et al. Among authors: huang y. Pharm Dev Technol. 2005;10(2):227-32. doi: 10.1081/pdt-54429. Pharm Dev Technol. 2005. PMID: 15926671

6

Transition metal-induced degradation of a pharmaceutical compound in reversed-phase liquid chromatographic analysis.

Wang Q, He BL, Zhang J, Huang Y, Kleintop B, Raglione T. Wang Q, et al. Among authors: huang y. J Pharm Biomed Anal. 2015;111:288-96. doi: 10.1016/j.jpba.2015.04.005. Epub 2015 Apr 15. J Pharm Biomed Anal. 2015. PMID: 25916912

7

Structural characterization of low level degradants in aztreonam injection and an innovative approach to aid HPLC method validation.

Ye Q, Ding W, Rinaldi F, Huang Y, Miller SA, Bolgar M. Ye Q, et al. Among authors: huang y. J Pharm Biomed Anal. 2016 May 30;124:358-364. doi: 10.1016/j.jpba.2016.03.017. Epub 2016 Mar 9. J Pharm Biomed Anal. 2016. PMID: 26991056

8

Degradation kinetics and mechanism of an oxadiazole derivative, design of a stable drug product for BMS-708163, a γ-secretase inhibitor drug candidate.

Hartley RF, Huang Y, Cassidy M, Razler TM, Qian F, Hussain MA. Hartley RF, et al. Among authors: huang y. J Pharm Sci. 2012 Sep;101(9):3124-33. doi: 10.1002/jps.23050. Epub 2012 Jan 19. J Pharm Sci. 2012. PMID: 22262489

9

An Unexpected Degradation Pathway of a 1,2,4-Triazolo[4,3-a]pyridine Derivative: The Formation of 2 Cationic Pseudodimers of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Drug Candidate in a Stressed Capsule Formulation.

Huang Y, Wang Q, Wu Y. Huang Y, et al. J Pharm Sci. 2018 Jun;107(6):1633-1641. doi: 10.1016/j.xphs.2018.02.009. Epub 2018 Feb 17. J Pharm Sci. 2018. PMID: 29458062

10

Oxidative degradation pathways of beclabuvir hydrochloride mediated by hydrogen peroxide and UV/Vis light.

Ye Q, Huang Y, Grier S, Miller SA. Ye Q, et al. Among authors: huang y. J Pharm Biomed Anal. 2019 Aug 5;172:388-394. doi: 10.1016/j.jpba.2019.05.017. Epub 2019 May 8. J Pharm Biomed Anal. 2019. PMID: 31100536

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81,801 results

Search Page

Filters